Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer

References

• Machlowska J , BajJ, SitarzMet al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int. J. Mol. Sci.21(11), 4012 (2020).
   PubMed Web of Science ®Google Scholar
• Ang TL , FockKM. Clinical epidemiology of gastric cancer. Singapore Med. J.55(12), 621 (2014).
   PubMed Web of Science ®Google Scholar
• Verstegen MH , HarkerM, VanDe Water Cet al. Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology. World J. Gastroenterol.26(39), 6037 (2020).
   PubMed Web of Science ®Google Scholar
• Pellino A , RielloE, NappoFet al. Targeted therapies in metastatic gastric cancer: current knowledge and future perspectives. World J. Gastroenterol.25(38), 5773 (2019).
   PubMed Web of Science ®Google Scholar
• Zhu Y , ZhuX, WeiXet al. HER2-targeted therapies in gastric cancer. Biochim. Biophys. Acta. Rev. Cancer1876(1), 188549 (2021).
   PubMed Web of Science ®Google Scholar
• Kelly CM , JanjigianYY. The genomics and therapeutics of HER2-positive gastric cancer – from trastuzumab and beyond. J. Gastrointest. Oncol.7(5), 750 (2016).
   PubMedGoogle Scholar
• Bang Y-J , Van CutsemE, FeyereislovaAet al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet376(9742), 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Rivera F , RomeroC, Jimenez-FonsecaPet al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother. Pharmacol.83(6), 1175–1181 (2019).
   PubMed Web of Science ®Google Scholar
• Soularue E , CohenR, TournigandCet al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bull. Cancer102(4), 324–331 (2015).
   PubMed Web of Science ®Google Scholar
• Zaanan A , PalleJ, SoularueEet al. Trastuzumab in combination with FOLFIRI in patients with advanced HER2-positive gastro-esophageal adenocarcinoma: a retrospective multicenter AGEO study. Target Oncol.13(1), 107–112 (2018).
   PubMed Web of Science ®Google Scholar
• Li Q , LiH, JiangHet al. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study. Clin. Transl. Oncol.20(6), 695–702 (2018).
   PubMed Web of Science ®Google Scholar
• Ryu M-H , YooC, KimJGet al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur. J. Cancer51(4), 482–488 (2015).
   PubMed Web of Science ®Google Scholar
• Gong J , LiuT, FanQet al. Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC cancer16(1), 1–9 (2016).
   Google Scholar
• Wagner AD , SynNL, MoehlerMet al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev.8(8), Cd004064 (2017).
   PubMedGoogle Scholar
• Aznab M , MaleksabetD, KhazaeiS, KhazaeiM, RezaeiM. The role of human epidermal growth factor receptor (HER2/neu) in the prognosis of patients with gastric cancer. Asian Pac. J. Cancer Prev.20(7), 1989 (2019).
   PubMedGoogle Scholar
• Ilhan-Mutlu A , TaghizadehH, BeerAet al. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: a retrospective single center analysis. Cancer Biol. Ther.19(3), 169–174 (2018).
   PubMed Web of Science ®Google Scholar
• Wang F , LiuT-S, YuanX-Let al. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. Am. J. Cancer Res.10(9), 3037 (2020).
   PubMed Web of Science ®Google Scholar
• Okita A , ImaiH, TakahashiMet al. Efficacy and safety of trastuzumab in combination with S-1 and cisplatin therapy for Japanese patients with HER2-positive advanced gastric cancer: retrospective analysis. Tohoku J. Exp. Med.245(2), 123–129 (2018).
   PubMed Web of Science ®Google Scholar
• Merchant S , KongW, GyawaliBet al. Effectiveness of trastuzumab in routine clinical practice: a population-based study of patients with HER-2-positive Oesophageal, gastroesophageal and gastric cancer. Clin. Oncol.33, 202–207 (2020).
   Web of Science ®Google Scholar
• Gürbüz M , AkkuşE, SakinAet al. Trastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: retrospective observational real-life data of Turkish Oncology Group. J. Gastrointest. Oncol.1–7 (2021).
   PubMedGoogle Scholar
• Basal FB , KaracinC, BilgetekinIet al. Response to trastuzumab treatment and number of cycles in Her2-positive metastatic gastric cancer survival. J. Coll. Physicians Surg. Pak.30(12), 1279–1284 (2020).
   PubMed Web of Science ®Google Scholar
• Li Q , LvM, JiangHet al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J. Cancer Res. Clin. Oncol.146(1), 287–295 (2020).
   PubMed Web of Science ®Google Scholar
• Al-Shamsi HO , FahmawiY, DahbourIet al. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J. Gastrointest. Oncol.7(4), 499 (2016).
   PubMedGoogle Scholar
• Li Q , JiangH, LiHet al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget7(31), 50656 (2016).
   PubMedGoogle Scholar
• Kadowaki S , MasuishiT, EtoTet al. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy. Cancer Chemother. Pharmacol.80(4), 807–813 (2017).
   PubMed Web of Science ®Google Scholar
• Pectasides E , StachlerMD, DerksSet al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov.8(1), 37–48 (2018).
   PubMed Web of Science ®Google Scholar
• Yi JH , KangJH, HwangIGet al. A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: in the perspectives of ethnicity and histology. Cancer Res. Treat.48(2), 553 (2016).
   PubMed Web of Science ®Google Scholar